Sai Life Sciences Reports Strong FY26 Results, Noting 29% Topline Growth and 109% Jump in Net Profit

Sai Life Sciences Reports Strong FY26 Results, Noting 29% Topline Growth and 109% Jump in Net Profit​

Sai Life Sciences Limited, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) in India, has announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The company reported significant year-over-year growth across key metrics, indicating strong performance in the global life sciences sector.

During the quarter, Sai Life Sciences highlighted its continued deepening of relationships with global pharmaceutical customers and its expansion of integrated CRDMO capabilities.

"FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth," stated Mr. Krishna Kanumuri, Managing Director and CEO of Sai Life Sciences Limited. He added that despite a dynamic operating environment, the long-term fundamentals of innovation-led outsourcing and supply chain diversification remain strong, positioning the company well for growth.

Mr. Siva Chittor, Chief Financial Officer, commented that "FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities."

Financial Performance Overview​

The company's financial results for the fiscal year ending March 31, 2026, showed substantial increases across the board.


*Note: PAT figures are before exceptional items.

Key Growth Drivers​

The reported financial growth was attributed to several key factors, including the deepening engagement with large pharma clients, sustained momentum in integrated discovery services, and strategic investments in new modalities and next-generation technologies.

Specific highlights from the financial reporting include:

• Revenue from Operations reached ₹2,192 Cr for FY26, marking a 29% increase compared to ₹1,695 Cr in FY25.
• EBITDA stood at ₹661 Cr in FY26, reflecting a 56% increase compared to ₹425 Cr in FY25.
• The Profit After Tax (PAT) was recorded at ₹355 Cr for FY26, an increase of 109% over ₹170 Cr in FY25.
• The company also incurred Capital Expenditure (Capex) of ₹633 Cr during the fiscal year.

Sai Life Sciences is positioned as one of India's fastest growing CRDMOs, partnering with innovator pharmaceutical and biotech companies. Headquartered in Hyderabad, India, the company provides integrated solutions that cover discovery, process development, clinical and commercial manufacturing, and advanced technology platforms globally. Sai Life Sciences focuses on delivering high-quality, cost-effective, and scalable solutions while adhering to the highest standards of safety and compliance.

SAILIFE Stock Price Movement​

On Thursday, Sai Life Sciences Limited shares rallied, settling at ₹1112.5, an uplift of 3.10% for the session. The stock traded on robust volume, hitting a notable intraday peak near its 52-week high of ₹1139.4.